5 Key Takeaways

• 1

  PER-001 is an investigational drug designed for long-term control of diabetic retinopathy by addressing underlying ischemia.

• 2

  The therapy, delivered via a dissolvable intravitreal implant, showed improvements in vision and retinal structure in clinical trials.

• 3

  In phase 2 trials, 37.5% of glaucoma patients receiving PER-001 experienced significant visual field improvements compared to controls.

• 4

  In diabetic retinopathy trials, patients showed gains in contrast sensitivity and visual acuity, along with structural improvements.

• 5

  Perfuse Therapeutics plans to advance PER-001 into pivotal studies for glaucoma and diabetic retinopathy in late 2025.